Advertisement
Canada markets closed

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7322
    -0.0001 (-0.01%)
     

  • CRUDE OIL

    83.89
    +0.32 (+0.38%)
     

  • Bitcoin CAD

    87,514.04
    -565.42 (-0.64%)
     

  • CMC Crypto 200

    1,382.89
    +0.32 (+0.02%)
     

  • GOLD FUTURES

    2,339.60
    -2.90 (-0.12%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,761.75
    +194.25 (+1.11%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,635.15
    +6.67 (+0.02%)
     

  • CAD/EUR

    0.6825
    +0.0004 (+0.06%)
     

Stocks in play: NeonMind Biosciences Inc.

Baystreet.ca
·1 min read

Announced today the appointment of Dr. Sagar Parikh, MD to its Specialty Clinics Advisory Board. In this role, Dr. Parikh will leverage his vast expertise in clinical treatment and interventional psychiatry including effectively treating patients with psychedelics such as ketamine, esketamine, and neurostimulation for mood and anxiety disorders to guide NeonMind as it develops specialty clinic services for communities in need. "Dr. Parikh brings unmatched experience to guide the development and integration of the most effective and cutting-edge protocols and treatment modalities for our expected specialty clinic rollout. We are committed to ensuring that every patient receives tailored, personalized care and each clinic is designed to meet needs of the local community where it will be located. Dr. Parikh's expert leadership will ensure that we offer best-in-class medical services and programs to every patient," said Robert Tessarolo, President & CEO of NeonMind. NeonMind Biosciences Inc. shares C.NEON are trading unchanged at $0.14.

Read: